Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MYC | P01106 | 1/20 | 0.42 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.38 |
| ▸ | HTR7 | P34969 | 2/20 | 0.37 |
| ▸ | CD44 | P16070 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA7 | P43166 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 2/20 | 0.31 |
| ▸ | CASP3 | P42574 | 2/20 | 0.31 |
| ▸ | RAB9A | P51151 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18805855 | 0.85 | PDK2 (0.38) | PDK2HTR7CA1CA2CA7 | |
| SCHEMBL196673 | 0.84 | NPC1 (0.36) | HTR7CA1CA2CA9TSHR | |
| SCHEMBL29548615 | 0.84 | NPC1 (0.36) | HTR7CA1CA2CA9TSHR | |
| SCHEMBL17930297 | 0.81 | NPC1 (0.30) | NPC1CASP3RAB9ASMN1; SMN2SENP7 | |
| SCHEMBL29492107 | 0.81 | ALDH1A1 (0.30) | NPC1CASP3RAB9ASENP7SENP6 | |
| SCHEMBL333685 | 0.81 | ALDH1A1 (0.30) | NPC1CASP3RAB9ASENP7SENP6 | |
| SCHEMBL2848640 | 0.80 | PTPRC (0.42) | PDK2CD44TSHRCYP3A4DPP4 | |
| SCHEMBL1156372 | 0.79 | TSHR (0.43) | CD44CA1CA2CA7CA9 | |
| SCHEMBL2620734 | 0.77 | TOP1 (0.42) | PDK2HTR7CA1CA2CA7 | |
| SCHEMBL3680534 | 0.75 | TRPA1 (0.44) | CD44CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2139839-B1 | A METHOD FOR PREPARATION OF 6-Ý3-(1-ADAMANTYL)-4-METHOXYPHENYL¨-2-NAPHTOIC ACID | GRINDEKS JSC (LV) | 2012-03-28 | — | — | EP | claimed |
| EP-2139838-B1 | A PROCESS FOR THE PREPARATION OF 6-[3-(1-ADAMANTYL)-4-METHOXYPHENYL]-2-NAPHTOIC ACID | GRINDEKS JSC (LV) | 2012-03-28 | — | — | EP | claimed |
| US-8119835-B2 | Method for preparation of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphtoic acid | JSC GRINDEKS (LV) | 2012-02-21 | — | — | US | claimed |
| US-20100160677-A1 | PROCESS FOR PREPARATION OF 6-[3-(1-ADMANTYL)-4-METHOXYPHENYL]-2-NAPHTOIC ACID. | JSC GRINDEKS (LV) | 2010-06-24 | — | — | US | claimed |
| US-20100076219-A1 | METHOD FOR PREPARATION OF 6-[3(1-ADAMANTYL) -4-METHOXYPHENYL]-2-NAPHTOIC ACID | JSC GRINDEKS (LV) | 2010-03-25 | — | — | US | claimed |
| EP-2139839-B1 | A METHOD FOR PREPARATION OF 6-Ý3-(1-ADAMANTYL)-4-METHOXYPHENYL¨-2-NAPHTOIC ACID | GRINDEKS JSC (LV) | 2012-03-28 | — | — | EP | disclosed |
| EP-2139838-B1 | A PROCESS FOR THE PREPARATION OF 6-[3-(1-ADAMANTYL)-4-METHOXYPHENYL]-2-NAPHTOIC ACID | GRINDEKS JSC (LV) | 2012-03-28 | — | — | EP | disclosed |
| US-8119835-B2 | Method for preparation of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphtoic acid | JSC GRINDEKS (LV) | 2012-02-21 | — | — | US | disclosed |
| US-20100160677-A1 | PROCESS FOR PREPARATION OF 6-[3-(1-ADMANTYL)-4-METHOXYPHENYL]-2-NAPHTOIC ACID. | JSC GRINDEKS (LV) | 2010-06-24 | — | — | US | disclosed |
| US-20100076219-A1 | METHOD FOR PREPARATION OF 6-[3(1-ADAMANTYL) -4-METHOXYPHENYL]-2-NAPHTOIC ACID | JSC GRINDEKS (LV) | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100076219-A1 | METHOD FOR PREPARATION OF 6-[3(1-ADAMANTYL) -4-METHOXYPHENYL]-2-NAPHTOIC ACID | HPD, DERA, DHCR7 | MYC 1626/4885PDK2 332/4885HTR7 1133/4885 |
| US-20100160677-A1 | PROCESS FOR PREPARATION OF 6-[3-(1-ADMANTYL)-4-METHOXYPHENYL]-2-NAPHTOIC ACID. | ME1, CD274, PDCD1LG2 | MYC 2806/4885PDK2 38/4885HTR7 1093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.